Please find enclosed herewith the Un-audited Financial Results of the Company for the quarter ended 31st December, 2026 as approved by the Board.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 5.4 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the quarter ended December 31, 2025, revenue from operations fell ~15% year-on-year to Rs. 4,482.69 lakhs (from Rs. 5,256.12 lakhs in Q3 FY25), while nine-month revenue declined ~10% to Rs. 13,082.58 lakhs. Despite the top-line drop, profit before tax surged to Rs. 854.70 lakhs in Q3 (from Rs. 424.19 lakhs, roughly doubling) and Rs. 2,658.82 lakhs for nine months (from Rs. 1,499.26 lakhs, up ~77%). Profit after tax also doubled in Q3 with EPS at Rs. 10.01 (vs Rs. 5.01) and 9M EPS at Rs. 29.08 (vs Rs. 16.47), reflecting strong margin expansion driven by lower raw material and operating costs. Statutory auditor Mahendra N. Shah & Co. issued a clean limited review report with no qualifications. Separately, the Board appointed Mr. Valan Raja Nadar (23+ years experience in finance) as the new Chief Financial Officer effective February 10, 2026.
Sharp improvement in profitability despite revenue contraction is a positive signal for shareholders — better cost control and margin expansion more than offset weak sales. However, sustained revenue decline is a watch-point; the new CFO appointment could bring a fresh strategic push on growth and efficiency.